Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated
12:47pm, Thursday, 02'nd Nov 2023
Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.
Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key Metrics
08:17pm, Wednesday, 01'st Nov 2023
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics comp
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
06:01am, Friday, 27'th Oct 2023
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
EXEL vs. TECH: Which Stock Is the Better Value Option?
12:47pm, Thursday, 12'th Oct 2023
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But which of these two stocks offers value investors
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
09:49am, Monday, 02'nd Oct 2023
Low-beta stocks allow investors to sleep well at night as the latest developments on interest rate hikes and their effects on the market cause anxiety. Despite things being slightly better than in pre
3 Biotech Stocks That Should Be on Every Investor's Radar This Fall
02:15pm, Wednesday, 20'th Sep 2023
The Federal Reserve's decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rates, drug discovery moves on.
Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico
12:46pm, Wednesday, 13'th Sep 2023
Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor.
Exelixis to license Insilico AI-designed cancer drug
08:40am, Tuesday, 12'th Sep 2023
Exelixis Inc. EXEL, -0.54% is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insilico Medicine's generative artificial intelligence
EXEL vs. ILMN: Which Stock Is the Better Value Option?
12:47pm, Tuesday, 05'th Sep 2023
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Illumina (ILMN). But which of these two stocks presents investors with the
Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why
12:01pm, Monday, 04'th Sep 2023
Exelixis' (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Its efforts to develop additional drugs to expand its portfolio are poised to reap rewards for the company.
Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade)
07:00am, Wednesday, 30'th Aug 2023
Exelixis issued two important releases regarding its lead molecule cabozantinib, showing positive results in prostate cancer and advanced pancreatic and extra-pancreatic neuroendocrine tumors. The com
Top 5 High-Flying Mid-Cap Stocks Despite a Volatile August
09:46am, Tuesday, 29'th Aug 2023
We have narrowed our search to five mid-cap stocks that have provided double-digit returns in the past month. These are: FN, FRSH, HRB, EXEL, PSN.
Exelixis: Positive Pancreatic Cancer Data Brings 2 Big Catalysts On Deck
06:03am, Sunday, 27'th Aug 2023
Phase 3 CABINET study, using CABOMETYX to treat patients with advanced pancreatic cancer and advanced pancreatic neuroendocrine tumors, stopped early due to overwhelming efficacy. Results from the pha
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
01:32pm, Friday, 25'th Aug 2023
Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
04:20pm, Monday, 21'st Aug 2023
The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon
